ProCE Banner Activity

Navigating the Latest Evidence and Strategies for Renal Risk Reduction in T2D

Slideset

This downloadable slideset provides an in-depth resource for healthcare professionals focusing on the latest evidence and strategies for renal risk reduction in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). It covers essential topics, including the mechanisms of action for GLP-1 receptor agonists, the efficacy and safety data relevant to their use, and guidance on integrating evidence-based therapies into clinical practice to optimize patient outcomes.

Released: October 31, 2024

Expiration: October 30, 2025

Share

Faculty

David Charytan

David Charytan, MD, MSc

Norman S. Wilker Professor of Medicine
Director, Nephrology Division
New York University Grossman School of Medicine
New York, New York

Jennifer B Green

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the American Kidney Fund.

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

American Kidney Fund

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner